Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.
Leukemia. 2010 Aug;24(8):1470-5. doi: 10.1038/leu.2010.139. Epub 2010 Jun 24.
Graft-versus-host disease (GVHD) is a frequent complication after hematopoietic cell transplant (HCT). Tissue damage as a result of chemoradiation injury is the initiating event in the pathogenesis of acute GVHD. Variations in DNA repair can influence the amount of tissue damage in response to alkylating agents and ionizing radiation used as conditioning during HCT. As DNA damage caused by these agents is repaired by the base excision repair (BER) pathway, we hypothesized that single-nucleotide polymorphisms (SNPs) in BER pathway will be associated with GVHD after HCT. Hence, we analyzed 179 SNPs in BER pathway in 470 recipients of allogeneic HCT for association with acute and chronic GVHD. In multivariate analysis, one SNP (rs6844176) in RFC1 (replication factor C (activator 1)) gene was independently associated with a higher risk of grade II-IV acute GVHD (relative risk (RR): 1.39, 95% confidence interval (CI): 1.14-1.70, P=0.001), and showed a trend toward higher risk of grade III-IV acute GVHD (RR: 1.33, 95% CI: 0.95-1.85, P=0.09). One SNP in PARP1 gene (rs1805410) was associated with a higher risk of chronic GVHD (RR: 1.81, 95% CI: 1.29-2.54, P=0.001). These results show that SNPs in the BER pathway can be used as genetic biomarkers to predict those at high risk for GVHD toward whom novel prophylactic strategies could be targeted.
移植物抗宿主病(GVHD)是造血细胞移植(HCT)后的常见并发症。化学放射损伤导致的组织损伤是急性 GVHD 发病机制中的起始事件。DNA 修复的变异会影响到 HCT 期间使用的烷化剂和电离辐射所导致的组织损伤程度。由于这些试剂引起的 DNA 损伤是通过碱基切除修复(BER)途径修复的,我们假设 BER 途径中的单核苷酸多态性(SNP)与 HCT 后的 GVHD 有关。因此,我们分析了 470 名异基因 HCT 受者的 179 个 BER 途径中的 SNP,以探讨其与急性和慢性 GVHD 的关系。在多变量分析中,RFC1(复制因子 C(激活剂 1))基因中的一个 SNP(rs6844176)与 II-IV 级急性 GVHD 的风险增加独立相关(相对风险(RR):1.39,95%置信区间(CI):1.14-1.70,P=0.001),并且与 III-IV 级急性 GVHD 的风险升高呈趋势相关(RR:1.33,95%CI:0.95-1.85,P=0.09)。PARP1 基因中的一个 SNP(rs1805410)与慢性 GVHD 的风险增加相关(RR:1.81,95%CI:1.29-2.54,P=0.001)。这些结果表明,BER 途径中的 SNP 可作为遗传生物标志物,用于预测那些患有 GVHD 的高危患者,针对这些患者可以采取新的预防策略。